Catalyst Dossier · compiled by CeliA 🧫

VYNE Therapeutics Inc. (VYNE)

Pharmaceutical Preparations · market cap $21M · as of 2026-07-18

Research and calibrated estimates, not financial advice — verify before acting.

Next catalyst

2026-08-13

Earnings

Pipeline

programs

Upcoming events

next 90d+

Dossier

Ready

cached

VYNE Therapeutics (VYNE) is a micro-cap pharmaceutical company with a $26M market cap, 13 employees, and $24.6M in cash providing roughly 18 months of runway. The company carries a broad dermatology-focused pipeline spanning multiple Phase 2 and Phase 3 assets, though it generates negligible revenue (~$1M annually) and has burned through capital consistently, posting a $26M net loss in 2025 on $19M of R&D spend. No analyst coverage exists and no recent clinical catalysts have been disclosed.

The catalyst path

2026-08-13Earningsimp 5/10

Pipeline

Asset	Phase	Indication
Serlopitant High Dose	Phase 2	Pruritus
3% Minocycline Foam	Phase 2	Acne Vulgaris
FDX104 (4% Doxycycline)	Phase 2	Rash Due to Epidermal Growth Factor Receptor Inhibitors
VPD-737	Phase 2	Chronic Pruritus
FMX101	Phase 3	Acne Vulgaris
MK0594	Phase 2	Urinary Incontinence
Topical Minocycline Foam FXFM244	Phase 2	Acne Vulgaris
FMX103 1.5%	Phase 3	Papulopustular Rosacea
FMX-101, 4% minocycline foam	Phase 3	Acne Vulgaris
FMX103 minocycline foam 1.5%	Phase 3	Facial Papulopustular Rosacea
5mg Serlopitant Tablets	Phase 3	Pruritus
serlopitant	Phase 2	Prurigo Nodularis
5 mg Serlopitant Tablets	Phase 2	Pruritus
VYN201 Gel	Phase 2	Non-segmental Vitiligo
FMX114	Phase 2	Atopic Dermatitis
FMX-103 1.5%	Phase 2	Rosacea

The full dossier is a Pro feature

Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.

See Pro

Sources & data

SEC filings — EDGAR filings for VYNE (10-K, 10-Q, S-3, 13D/G, Form 4)
Clinical trials — 16 registered trials on ClinicalTrials.gov (per-trial NCT links in the pipeline)
Market & financial data — Financial Modeling Prep / financialdata.net — prices, statements, key metrics, insider & institutional filings.
Regulatory — openFDA, FDA advisory & PDUFA calendars.

Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.

Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, Financial Modeling Prep). Compiled by CeliA. Not financial advice.